Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. April 2015 08:01 ET | Quelle: Celldex Therapeutics, Inc.

Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies

HAMPTON, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today preclinical results that further support varlilumab's expansion into combination studies with...
06. April 2015 16:01 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology

HAMPTON, N.J., April 6, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer...
06. April 2015 08:01 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma

HAMPTON, N.J., April 6, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational...
17. März 2015 08:01 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A

HAMPTON, N.J., March 17, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that it has entered into a clinical trial collaboration with Roche to evaluate the safety,...
03. März 2015 10:00 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health Care Conference

HAMPTON, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company is scheduled to present a corporate overview at the Cowen and Company 35th...
27. Februar 2015 13:25 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares

HAMPTON, N.J., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the underwriters of its previously announced public offering of common stock have...
25. Februar 2015 18:48 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Therapeutics Prices Public Offering of Common Stock

HAMPTON, N.J., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 7,250,000 shares of its common stock,...
24. Februar 2015 16:00 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it is offering 7.25 million shares of its common stock in a proposed underwritten public...
24. Februar 2015 07:00 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Reports Fourth Quarter and Year-End 2014 Results

HAMPTON, N.J., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,...
23. Februar 2015 08:01 ET | Quelle: Celldex Therapeutics, Inc.

Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma

HAMPTON, N.J., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the U.S. Food and Drug Administration (FDA) has granted rindopepimut (Rintega®)...

Vorherige Seite